drugset / Trial / NCT01271387
Pharmacokinetics of Tasimelteon in Subjects With Mild or Moderate Hepatic Impairment
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this research study is to understand whether there is any difference in the amount of tasimelteon (including its breakdown products) in the blood in individuals with mild or moderate liver disease compared to individuals who have normal liver function.
Timeline
- Start
- 2011-01
- Primary completion
- 2011-08
- Completion
- 2011-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | tasimelteon | Small molecule | 20 mg | Oral |
Indications
No indication recorded.